Since Aclaris was founded in 2012, our focus has been innovation to help people with underserved dermatologic conditions, taking inspiration from some of the patients our founders saw in clinical practice as dermatologists. We're identifying early-stage drug candidates to create novel medicines for skin and hair disorders. We've built a committed, patient-centric organization of nearly 200 employees, guided by leaders with 250+ years of combined experience in developing and commercializing treatments in dermatology and immunology. Source
No articles found.
ImmunoGen is developing the next generation of antibody-drug conjugates (ADCs) to ...
ImmunoGen is developing the next generation of ...
Verastem Oncology (Nasdaq: VSTM) is a commercial biopharmaceutical company committ...
Verastem Oncology (Nasdaq: VSTM) is a commercia...
Savara is an orphan lung disease company. Savaraâs pipeline comprises Molgradex,...
Savara is an orphan lung disease company. Savar...
Ovid Therapeutics is a biopharmaceutical company focused exclusively on developing...
Ovid Therapeutics is a biopharmaceutical compan...
Syros is redefining the power of small molecules to control the expression of gene...
Syros is redefining the power of small molecule...
Spark Therapeutics, a fully integrated company, strives to challenge the inevitabi...
Spark Therapeutics, a fully integrated company,...
Join the National Investor Network and get the latest information with your interests in mind.